The Age-Dependent Increase of Metabolic Syndrome Requires More Extensive and Aggressive Non-Pharmacological and Pharmacological Interventions: A Cross-Sectional Study in an Italian Cohort of Obese Women

Table 4

Obese patients with or without metabolic syndrome, subdivided among age ranges, treated with hypolipidaemic drugs, hypoglycaemics, and/or antihypertensives.

	Treated
	18–30	31–40	41–50	51–60	61–70	>70	β1	Y-intercept
Hypolipidaemics
MetS+	2/25 (8.0%)	9/54 (16.7%)^a	9/117 (7.7%)^a	45/203 (22.2%)^a	41/182 (22.5%)^a	11/49 (22.4%)	0.0042	−0.05	0.001
MetS−	0/73 (0%)	0/52 (0%)	0/79 (0%)	0/89 (0%)	0/57 (0%)	0/20 (0%)	—	—	—
Hypoglycaemics
MetS+	3/25 (12.0%)^a	12/54 (22.2%)^a	26/117 (22.2%)^a	78/203 (38.4%)^a	60/182 (33.0%)^a	20/49 (40.8%)^a	0.0057	−0.001	<0.001
MetS−	0/73 (0%)	0/52 (0%)	0/79 (0%)	1/89 (1.1%)	1/57 (1.8%)	0/20 (0%)	0.0002	−0.01	0.319
Antihypertensives
MetS+	7/25 (28.0%)^a	26/54 (48.1%)^a	79/117 (67.5%)^a	159/203 (78.3%)	155/182 (85.2%)^a	43/49 (87.8%)	0.0115	0.11	<0.001
MetS−	1/73 (1.4%)	6/52 (11.5%)	22/79 (27.8%)	47/89 (52.8%)	28/57 (49.1%)	14/20 (70.0%)	0.0140	−0.34	<0.001

Values are expressed in percent (% to the number of patients within the corresponding age range). Abbreviations: MetS−, negative for metabolic syndrome; MetS+, positive for metabolic syndrome. ^a vs. the corresponding MetS− subgroup (Fisher’s exact test). Values of β₁, Y-intercept and p refer to the linear regression performed by using all data within each subgroup (MetS+ or MetS−). The symbol “—” means non-determinable or non-applicable.